Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00828711 · ClinicalTrials.gov registry record · Phase 2
Misoprostol Vaginal Insert (MVI) 100, 150, 200 mcg for Cervical Ripening and Induction of Labor
A Phase 2 study of Cervical Ripening and Induction of Labor, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 374
- Enrollment target
- 11
- Study locations
NCT00828711: Completed Phase 2 study of Cervical Ripening and Induction of Labor, sponsored by Ferring Pharmaceuticals.
NCT00828711 is a Phase 2 study of Cervical Ripening and Induction of Labor that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 374 participants, below the 424-participant average among 8 other Cervical Ripening trials with a reported enrollment target (12% lower). The trial reports 11 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00828711, a Phase 2 study of Cervical Ripening and Induction of Labor, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 374 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of the 100, 150 and 200 mcg Misoprostol Vaginal Insert (MVI 100, MVI 150 and MVI 200) for women requiring cervical ripening and induction of labor.
Conditions Studied
Interventions
- DRUG MVI 200
- DRUG MVI 100
- DRUG MVI 150
Study Locations (11)
Arizona
- Precision Trials - Phoenix
- Tuscon Medical Center - Tucson
California
- Long Beach Memorial Medical Center - Long Beach
- UCI Medical Center - Orange
North Carolina
- Duke University Medical Center - Durham
- Forsyth Medical Center - Winston-Salem
New Mexico
- University of New Mexico Medical Center - Albuquerque
Pennsylvania
- Temple University Hospital - Philadelphia
South Carolina
- Greenville Hospital System - Greenville
Tennessee
- University of Tennesse Medical Center - Knoxville
Texas
- University of Texas Health Sciences Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 374 participants |
| Start Date | 2009-04 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
What the finished NCT00828711 record still lists
NCT00828711 is an interventional study that assigns participants to a tested intervention. The registered 374 participants enrollment target is mid-sized for trials with a published cap, below the 424-participant average among 8 other Cervical Ripening trials with a reported enrollment target (12% lower).
The record links to 2 conditions, with Cervical Ripening appearing as the primary indexed condition, and to 3 interventions - of which MVI 200 is the first listed.
NCT00828711 lists 11 locations in 8 states (Arizona, California, North Carolina).
Frequently Asked Questions
What is clinical trial NCT00828711 about?
NCT00828711 is a clinical study titled "Misoprostol Vaginal Insert (MVI) 100, 150, 200 mcg for Cervical Ripening and Induction of Labor". The purpose of this study is to assess the efficacy and safety of the 100, 150 and 200 mcg Misoprostol Vaginal Insert (MVI 100, MVI 150 and MVI 200) for women requiring cervical ripening and induction of labor.
What is the current status of trial NCT00828711?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 374 participants. The study started on 2009-04. Estimated completion is 2009-12.
What conditions does trial NCT00828711 study?
This clinical trial studies the following conditions: Cervical Ripening, Induction of Labor.
What interventions are being tested in trial NCT00828711?
The interventions under investigation include: MVI 200 (DRUG), MVI 100 (DRUG), MVI 150 (DRUG).
Who is sponsoring clinical trial NCT00828711?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00828711 being conducted?
This trial has 11 study locations across Arizona, California, New Mexico, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Ripening
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00828711's enrollment target sits among peer trials
374 3rd of 8 higher than 6 of 8 other Cervical Ripening trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cervical Ripening trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pharmacokinetic (PK) Study of the 200 Microgram (mcg) Misoprostol Vaginal Insert (MVI 200) in Women at Term Gestation (The MVI-PK Study)
COMPLETED · Phase 2
-
Randomized Trial Comparing Misoprostol and Foley Bulb for Labor Induction in the Preterm Gestation
COMPLETED · Phase 2
-
Patient Satisfaction During Outpatient Versus Inpatient Foley Catheter Induction of Labor
COMPLETED · NA
-
Foley Catheter Compared to the Foley Catheter Alone for Cervical Ripening
COMPLETED · NA
-
Study of the Effectiveness of Cervical Ripening Balloon With and Without Oxytocin
COMPLETED · Phase 3
-
Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03686124 · 375 participants · Phase 1
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- NCT04059172 · 375 participants · Early Phase 1
Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management
- NCT04134923 · 375 participants
Imaging Biomarkers in Preclinical and Symptomatic AD
- NCT04569747 · 375 participants · Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia